487 related articles for article (PubMed ID: 31962173)
1. Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force.
Wang Z; Zhi K; Ding Z; Sun Y; Li S; Li M; Pu K; Zou J
Semin Cancer Biol; 2021 Feb; 69():77-90. PubMed ID: 31962173
[TBL] [Abstract][Full Text] [Related]
2. An Up-to-date Review on Protein-based Nanocarriers in the Management of Cancer.
Almalki WH
Curr Drug Deliv; 2024; 21(4):509-524. PubMed ID: 37165498
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
Ali ES; Sharker SM; Islam MT; Khan IN; Shaw S; Rahman MA; Uddin SJ; Shill MC; Rehman S; Das N; Ahmad S; Shilpi JA; Tripathi S; Mishra SK; Mubarak MS
Semin Cancer Biol; 2021 Feb; 69():52-68. PubMed ID: 32014609
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy.
Raj S; Khurana S; Choudhari R; Kesari KK; Kamal MA; Garg N; Ruokolainen J; Das BC; Kumar D
Semin Cancer Biol; 2021 Feb; 69():166-177. PubMed ID: 31715247
[TBL] [Abstract][Full Text] [Related]
6. Implications of nanotechnology for the treatment of cancer: Recent advances.
Klochkov SG; Neganova ME; Nikolenko VN; Chen K; Somasundaram SG; Kirkland CE; Aliev G
Semin Cancer Biol; 2021 Feb; 69():190-199. PubMed ID: 31446004
[TBL] [Abstract][Full Text] [Related]
7. Functionalized mesoporous silica nanoparticles in anticancer therapeutics.
Barkat A; Beg S; Panda SK; S Alharbi K; Rahman M; Ahmed FJ
Semin Cancer Biol; 2021 Feb; 69():365-375. PubMed ID: 31442571
[TBL] [Abstract][Full Text] [Related]
8. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic interventions in cancer treatment using protein and peptide-based targeted smart systems.
Zafar S; Beg S; Panda SK; Rahman M; Alharbi KS; Jain GK; Ahmad FJ
Semin Cancer Biol; 2021 Feb; 69():249-267. PubMed ID: 31442570
[TBL] [Abstract][Full Text] [Related]
10. Horizons of nanotechnology applications in female specific cancers.
Rajitha B; Malla RR; Vadde R; Kasa P; Prasad GLV; Farran B; Kumari S; Pavitra E; Kamal MA; Raju GSR; Peela S; Nagaraju GP
Semin Cancer Biol; 2021 Feb; 69():376-390. PubMed ID: 31301361
[TBL] [Abstract][Full Text] [Related]
11. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
12. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
Yu HP; Aljuffali IA; Fang JY
Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
[TBL] [Abstract][Full Text] [Related]
13. Membrane-core nanoparticles for cancer nanomedicine.
Guo J; Huang L
Adv Drug Deliv Rev; 2020; 156():23-39. PubMed ID: 32450105
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in nanomedicine for enhanced cancer chemotherapy.
Wei G; Wang Y; Yang G; Wang Y; Ju R
Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
[TBL] [Abstract][Full Text] [Related]
15. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
16. Protein-driven nanomedicines in oncotherapy.
Casanova I; Unzueta U; Arroyo-Solera I; Céspedes MV; Villaverde A; Mangues R; Vazquez E
Curr Opin Pharmacol; 2019 Aug; 47():1-7. PubMed ID: 30685732
[TBL] [Abstract][Full Text] [Related]
17. Passive and Active Drug Targeting: Role of Nanocarriers in Rational Design of Anticancer Formulations.
Das RP; Gandhi VV; Singh BG; Kunwar A
Curr Pharm Des; 2019; 25(28):3034-3056. PubMed ID: 31470779
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles for Cancer Targeting: Current and Future Directions.
Swain S; Sahu PK; Beg S; Babu SM
Curr Drug Deliv; 2016; 13(8):1290-1302. PubMed ID: 27411485
[TBL] [Abstract][Full Text] [Related]
19. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers.
Aljuffali IA; Fang CL; Chen CH; Fang JY
Curr Pharm Des; 2016; 22(27):4219-31. PubMed ID: 27323758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
